113 related articles for article (PubMed ID: 21719364)
21. Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study.
Davies MJ; Donnelly R; Barnett AH; Jones S; Nicolay C; Kilcoyne A
Diabetes Obes Metab; 2009 Dec; 11(12):1153-62. PubMed ID: 19930005
[TBL] [Abstract][Full Text] [Related]
22. Healthcare resource utilization and costs assessment of type 2 diabetes patients initiating exenatide BID or glargine: a retrospective database analysis.
Pawaskar M; Zagar A; Sugihara T; Shi L
J Med Econ; 2011; 14(1):16-27. PubMed ID: 21158486
[TBL] [Abstract][Full Text] [Related]
23. Health and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of type 2 diabetes: a simulation analysis.
Gaebler JA; Soto-Campos G; Alperin P; Cohen M; Blickensderfer A; Wintle M; Maggs D; Hoogwerf B; Han J; Pencek R; Peskin B
Vasc Health Risk Manag; 2012; 8():255-64. PubMed ID: 22566747
[TBL] [Abstract][Full Text] [Related]
24. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
25. A short-term cost-utility analysis of insulin degludec versus insulin glargine U100 in patients with type 1 or type 2 diabetes in Denmark.
Pollock RF; Tikkanen CK
J Med Econ; 2017 Mar; 20(3):213-220. PubMed ID: 27705031
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness analysis of liraglutide versus sitagliptin or exenatide in patients with inadequately controlled Type 2 diabetes on oral antidiabetic drugs in Greece.
Tzanetakos C; Melidonis A; Verras C; Kourlaba G; Maniadakis N
BMC Health Serv Res; 2014 Sep; 14():419. PubMed ID: 25245666
[TBL] [Abstract][Full Text] [Related]
27. Combination therapy with insulin glargine and exenatide: real-world outcomes in patients with type 2 diabetes.
Levin P; Wei W; Wang L; Pan C; Douglas D; Baser O
Curr Med Res Opin; 2012 Mar; 28(3):439-46. PubMed ID: 22216894
[TBL] [Abstract][Full Text] [Related]
28. Metabolic outcomes of elderly patient populations initiating exenatide BID versus insulin glargine in an ambulatory care setting.
Pawaskar M; Li Q; Reynolds MW
Curr Med Res Opin; 2012 Jun; 28(6):991-7. PubMed ID: 22519390
[TBL] [Abstract][Full Text] [Related]
29. Long-Term Effectiveness and Cost-Effectiveness of Metformin Combined with Liraglutide or Exenatide for Type 2 Diabetes Mellitus Based on the CORE Diabetes Model Study.
Zhang X; Liu S; Li Y; Wang Y; Tian M; Liu G
PLoS One; 2016; 11(6):e0156393. PubMed ID: 27304904
[TBL] [Abstract][Full Text] [Related]
30. The short-term cost-effectiveness of once-daily liraglutide versus once-weekly exenatide for the treatment of type 2 diabetes mellitus in the United States.
Wang B; Roth JA; Nguyen H; Felber E; Furnback W; Garrison LP
PLoS One; 2015; 10(4):e0121915. PubMed ID: 25849542
[TBL] [Abstract][Full Text] [Related]
31. Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands.
Hunt B; Malkin SJP; Moes RGJ; Huisman EL; Vandebrouck T; Wolffenbuttel BHR
BMJ Open Diabetes Res Care; 2019; 7(1):e000705. PubMed ID: 31641522
[TBL] [Abstract][Full Text] [Related]
32. Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes.
Shao N; Kuang HY; Hao M; Gao XY; Lin WJ; Zou W
Diabetes Metab Res Rev; 2014 Sep; 30(6):521-9. PubMed ID: 24823873
[TBL] [Abstract][Full Text] [Related]
33. Patient characteristics, drug adherence patterns, and hypoglycemia costs for patients with type 2 diabetes mellitus newly initiated on exenatide or insulin glargine.
Fabunmi R; Nielsen LL; Quimbo R; Schroeder B; Misurski D; Wintle M; Wade R
Curr Med Res Opin; 2009 Mar; 25(3):777-86. PubMed ID: 19203299
[TBL] [Abstract][Full Text] [Related]
34. Metabolic outcomes of matched patient populations initiating exenatide BID vs. insulin glargine in an ambulatory care setting.
Pawaskar M; Li Q; Hoogwerf BJ; Reynolds MW; Faries D; Engelman W; Bruhn D; Bergenstal RM
Diabetes Obes Metab; 2012 Jul; 14(7):626-33. PubMed ID: 22321776
[TBL] [Abstract][Full Text] [Related]
35. Exenatide: a review of its use in patients with type 2 diabetes mellitus (as an adjunct to metformin and/or a sulfonylurea).
Cvetković RS; Plosker GL
Drugs; 2007; 67(6):935-54. PubMed ID: 17428109
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of exenatide versus insulin glargine for the impact on endothelial functions and cardiovascular risk markers.
Gurkan E; Tarkun I; Sahin T; Cetinarslan B; Canturk Z
Diabetes Res Clin Pract; 2014 Dec; 106(3):567-75. PubMed ID: 25458329
[TBL] [Abstract][Full Text] [Related]
37. Estimating the long-term cost-effectiveness of exenatide in the United States: an adjunctive treatment for type 2 diabetes mellitus.
Minshall ME; Oglesby AK; Wintle ME; Valentine WJ; Roze S; Palmer AJ
Value Health; 2008; 11(1):22-33. PubMed ID: 18237357
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of Insulin Degludec Versus Insulin Glargine in Insulin-naive Chinese Patients With Type 2 Diabetes.
Cheng H; Wan X; Ma J; Wu B
Clin Ther; 2019 Mar; 41(3):445-455.e4. PubMed ID: 30713016
[TBL] [Abstract][Full Text] [Related]
39. Costs and consequences associated with newer medications for glycemic control in type 2 diabetes.
Sinha A; Rajan M; Hoerger T; Pogach L
Diabetes Care; 2010 Apr; 33(4):695-700. PubMed ID: 20056950
[TBL] [Abstract][Full Text] [Related]
40. Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes.
Secnik Boye K; Matza LS; Oglesby A; Malley K; Kim S; Hayes RP; Brodows R
Health Qual Life Outcomes; 2006 Oct; 4():80. PubMed ID: 17034640
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
